PlayStation Vita PS PlayStation 5 life comeback, according to a Sony patent - Despite the fact that Microsoft has already given some new brushstrokes of its next-generation console with the presentation of its Xbox Series s, Sony remains silent about PlayStation 5 and for the moment, everything that circulates on the Internet are rumors.

The last detail that catches the eye and that will delight the nostalgic has detected Gamerant that echoes a patent registered in February 2020 by the company that shows a possible compatibility between PS5 and PlayStation Vita and PSP, the portable consoles of Sony.

As you can see in the patent image, you can see both consoles, but what is not known is what kind of interaction it might have with these devices.

PlayStation Vita PS PlayStation 5 life comeback

The most sure thing, if it eventually comes true, is that they benefit from the functionality Remote Play, an application already available on PlayStation 4 that allows you to play the titles of the desktop console on phones, PC or anywhere you can install the application.

What is clear is that it is very difficult to think of a new portable console from Sony, because despite having a good catalog of titles, both machines did not enjoy good sales.

End of PlayStation Vita PS PlayStation 5 life comeback

More on

All you need to know about the coronavirus vaccine that will arrive in Spain before the end of the Year: who is behind it, when it will be approved, advantages and disadvantages

The AstraZeneca vaccine developed by the University of Oxford will arrive in Spain in December, as announced by the Minister of Health, Salvador Illa, who assured that the country would count on 3 million doses by the end of the year.

This has been made possible by the fact that Spain has joined the centralized purchase of this vaccine made through the European Union, for which it corresponds to 30 million doses. Our country is one of seven that are part of the negotiating team that acts as an interlocutor with the companies that are developing a vaccine.

The agreement forms part of the European strategy that the European Commission presented on 14 August to accelerate the development, manufacture and deployment of effective and safe vaccines against COVID-19 through the Advance Purchase Agreement for vaccines against COVID-19.

'In exchange for the right to purchase a certain number of vaccine doses in a given period, the commission would finance part of the initial costs of vaccine producers through an advance market commitment. The funding provided would be seen as a payment on account of vaccines that member states actually buy," the agency explains.

"Because the high cost and high failure rate make investing in a COVID-19 vaccine a high-risk decision for vaccine developers, these commitments will allow for investments that would otherwise likely not occur," he adds.

The promising vaccine from Oxford University has been supported since the beginning of its development. Soon AstraZeneca joined the project and also the world's largest vaccine manufacturer, India's Serum Institute, pledged to manufacture 40 million doses by September.

If tests progress at the pace Oxford Vaccine Group expects, it could be the first vaccine to be marketed in western markets. However, experts have been warning that more than one vaccine will be needed to meet demand and that the first to arrive will probably not be the most effective.

This could also be true for the Oxford: this is all you need to know about the vaccine that will arrive in Spain in September.

The vaccine has been developed by the University of Oxford Vaccine Group in collaboration with pharmaceutical giant Astra Zeneca.

"It uses an adenovirus viral vector that expresses the protein s", explains Isabel Sola, titular scientist and co-director with Luis Enjuanes of the coronavirus Laboratory of the National Biotechnology Center (CNB) of the Superior Council of Scientific Research (CSIC), in an interview with Business Insider Spain.

The researcher explains that the protein in question is one of the structural proteins of the virus and responsible for getting it to adhere to the cell and infect it.

The vaccine is already being tested on more than 10,000 volunteers as part of Phase 3 trials and they expect their vaccine to be ready for possible emergency use in the fall.

The economic details of the EC agreement with Astra Zeneca have not transcended. The company has assured that it will sell at cost price and that the manufacture of each dose costs only a couple of dollars. According to statements collected by Reuters, the Italian Health Minister would have encrypted the cost of each dose at 2.5 euros.

Early data reveal that it induces immunity without serious side effects. Isabel Sola confirms that the use of adenovirus has already shown its effectiveness in immunizing against other diseases.

The scientist claims that the main advantage of this vaccine candidate is that "its effectiveness is known" and it is known that it does not cause serious side effects.

In addition, when using an adenovirus, it has a very high capacity of replication, which facilitates its production to be done on a large scale, as explained researcher Adrian Hill, of the University of Oxford, in a webinar on COVID-19 of the Spanish Society of Rheumatology (SER).

"The viral vector expresses protein s, but we know that there are other vital proteins," warns Isabel Sola. The scientist points out that protein s has been shown to be relevant for the production of neutralizing antibodies, but that the cellular response is becoming more relevant, especially as it is confirmed that the antibodies disappear in a short time.

Only adventure that when the final results are known in October-November "we may see that the protection is not one hundred percent". The expert points out that this could simply imply that the vaccine requires a second dose, but warns of the increased costs and effort that this would entail for manufacturing and distribution.

If the protection is not one hundred percent, the scientist does not believe that it is a cause for concern and says that "for the moment, it is sufficient".

The last remaining unknown about the vaccine is how long the immunity it induces lasts. "We will not know how long the immunity lasts, because it will not have given time to follow the volunteers for a long time," says Sola.

You may also find interesting: